The maintenance of the $325 million to $345 million revenue guidance for full-year 2026 signals that CorMedix does not see any material deviation from its August forecast based on third quarter activity. The company separately disclosed that it held approximately $355 million in cash …
Mecasermin is a recombinant form of insulin-like growthFactor1 (IGF-1), a naturally occurring protein involved in growth and neurological development. Eton's hypothesis, derived from research led by Dr. John W. Swann at Baylor College of Medicine, is that impaired IGF-1 signaling in the brain may …
The new platform, called HarrowRx, functions as a licensed pharmacy registered on the Surescripts network. That means eyecare professionals can locate it in their EMR's pharmacy finder using the name, a National Council for Prescription Drug Programs identifier, or a National Provider Identifier number, …
Total revenues for the third quarter reached $1.214 billion, representing 10% growth on both a reported and organic basis. The Companion Animal Group, which forms the core of IDEXX's business, grew at the same 10% rate, with CAG DiagnosticsRecurring Revenue— the highest-margin and most …
The transaction is structured through a Chapter 11 plan that Karyopharm will seek court approval for, including approval of bidding procedures that allow other parties to submit competing proposals for the company's assets. This competitive bidding structure is designed to maximize value for all …
VYJUVEK, the company's approved gene therapy for dystrophic epidermolysis bullosa (DEB), generated $127.3 million in global net product revenue during the third quarter of 2026, a 30% increase from the same period a year earlier. GrossMarginfor the quarter was 94%, a figure that reflects …
Data presented at TCT 2026 indicated that approximately 84% of aortic valve calcification cases detectable on existing CT scans are not being reported through standard clinical workflows. Aortic valve calcification is a precursor to aortic stenosis, a narrowing of the heart's main outflow valve …
The Society for Neuro-Oncology annual meeting is one of the most important scientific gatherings for researchers, oncologists, and pharmaceutical developers focused on cancers of the central nervous system. Having two separate poster presentations at the event gives NeOnc an opportunity to showcase the breadth …
Prof. Tackenberg brings a career that spans academic neurology, pharmaceutical development, and medical affairs leadership. He joins Oculis from Roche, where he served as Head of Integrative Neuroscience and Medical Practice, overseeing clinical development plans, biomarker development strategies, and partnerships with scientific institutions.
• Orthocell holds a 12%Equityinterest in Marine Biomedical following a strategicInvestmentfinalised in January 2026, and has secured a first right of refusal over global distribution rights for PearlBone and future bone repair products.